ZLAB Quote, Financials, Valuation and Earnings

China Pharma Holding has a net margin of -45.49% compared to Zai Lab's net margin of -101.61%. Zai Lab's return on equity of -33.29% beat China Pharma Holding's return on equity of -66.27%.

Zai Lab has a consensus price target of $54.59, signalling upside risk potential of 90.74%. On the other hand China Pharma Holding has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab has higher upside potential than China Pharma Holding, analysts believe Zai Lab is more attractive than China Pharma Holding.

Zai Lab has a beta of 1.037, which suggesting that the stock is 3.742% more volatile than S&P 500. In comparison China Pharma Holding has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.629%.

Zai Lab has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab pays -- of its earnings as a dividend. China Pharma Holding pays out -- of its earnings as a dividend.

Zai Lab quarterly revenues are $106.5M, which are larger than China Pharma Holding quarterly revenues of $1.1M. Zai Lab's net income of -$48.4M is lower than China Pharma Holding's net income of -$1.1M. Notably, Zai Lab's price-to-earnings ratio is -- while China Pharma Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab is 6.95x versus 0.81x for China Pharma Holding. Usually stocks with elevated PS ratios are considered overvalued.

Dr Reddy's Laboratories has a net margin of -45.49% compared to Zai Lab's net margin of 18.73%. Zai Lab's return on equity of -33.29% beat Dr Reddy's Laboratories's return on equity of 18.25%.

Zai Lab has a consensus price target of $54.59, signalling upside risk potential of 90.74%. On the other hand Dr Reddy's Laboratories has an analysts' consensus of $14.42 which suggests that it could grow by 2.26%. Given that Zai Lab has higher upside potential than Dr Reddy's Laboratories, analysts believe Zai Lab is more attractive than Dr Reddy's Laboratories.

Zai Lab has a beta of 1.037, which suggesting that the stock is 3.742% more volatile than S&P 500. In comparison Dr Reddy's Laboratories has a beta of 0.326, suggesting its less volatile than the S&P 500 by 67.42%.

Zai Lab has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dr Reddy's Laboratories offers a yield of 0.68% to investors and pays a quarterly dividend of $0.10 per share. Zai Lab pays -- of its earnings as a dividend. Dr Reddy's Laboratories pays out 11.78% of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zai Lab quarterly revenues are $106.5M, which are smaller than Dr Reddy's Laboratories quarterly revenues of $982M. Zai Lab's net income of -$48.4M is lower than Dr Reddy's Laboratories's net income of $183.9M. Notably, Zai Lab's price-to-earnings ratio is -- while Dr Reddy's Laboratories's PE ratio is 21.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab is 6.95x versus 3.06x for Dr Reddy's Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech has a net margin of -45.49% compared to Zai Lab's net margin of --. Zai Lab's return on equity of -33.29% beat Sinovac Biotech's return on equity of -1.05%.

Zai Lab has a consensus price target of $54.59, signalling upside risk potential of 90.74%. On the other hand Sinovac Biotech has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab has higher upside potential than Sinovac Biotech, analysts believe Zai Lab is more attractive than Sinovac Biotech.

Zai Lab has a beta of 1.037, which suggesting that the stock is 3.742% more volatile than S&P 500. In comparison Sinovac Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Zai Lab has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab pays -- of its earnings as a dividend. Sinovac Biotech pays out -328.35% of its earnings as a dividend.

Zai Lab quarterly revenues are $106.5M, which are larger than Sinovac Biotech quarterly revenues of --. Zai Lab's net income of -$48.4M is higher than Sinovac Biotech's net income of --. Notably, Zai Lab's price-to-earnings ratio is -- while Sinovac Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab is 6.95x versus 1.49x for Sinovac Biotech. Usually stocks with elevated PS ratios are considered overvalued.

111 has a net margin of -45.49% compared to Zai Lab's net margin of -0.52%. Zai Lab's return on equity of -33.29% beat 111's return on equity of -21.67%.

Zai Lab has a consensus price target of $54.59, signalling upside risk potential of 90.74%. On the other hand 111 has an analysts' consensus of -- which suggests that it could grow by 660.01%. Given that 111 has higher upside potential than Zai Lab, analysts believe 111 is more attractive than Zai Lab.

Zai Lab has a beta of 1.037, which suggesting that the stock is 3.742% more volatile than S&P 500. In comparison 111 has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.823%.

Zai Lab has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 111 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab pays -- of its earnings as a dividend. 111 pays out -- of its earnings as a dividend.

Zai Lab quarterly revenues are $106.5M, which are smaller than 111 quarterly revenues of $534.8M. Zai Lab's net income of -$48.4M is lower than 111's net income of -$2.8M. Notably, Zai Lab's price-to-earnings ratio is -- while 111's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab is 6.95x versus 0.03x for 111. Usually stocks with elevated PS ratios are considered overvalued.